Amphastar Pharmaceuticals
AMPH
129 hedge funds and large institutions have $522M invested in Amphastar Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 42 increasing their positions, 53 reducing their positions, and 16 closing their positions.
7% more capital invested
Capital invested by funds: $489M → $522M (+$33.5M)
0.4% less ownership
Funds ownership: 55.13% → 54.73% (-0.4%)
5% less funds holding
Funds holding: 136 → 129 (-7)
21% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 53
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$9.45M |
| 2 |
BlackRock
New York
|
+$4.69M |
| 3 |
Morgan Stanley
New York
|
+$4.57M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.33M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$5.28M |
| 2 |
Two Sigma Investments
New York
|
-$3.54M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$2.36M |
| 4 |
Two Sigma Advisers
New York
|
-$2.25M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$2.01M |
AMPH Hedge Fund Activity: Q4 2020 in Review
129 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q4 2020, worth a combined $522M — up 6.9% from $489M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AMPH and 9 opened new positions — a net loss of 7 holders — while 53 trimmed existing stakes and 42 added.
The largest buyer was Federated Hermes, adding an estimated $9.45M. The largest seller was Fuller & Thaler Asset Management, cutting an estimated $5.28M.
- 129 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q4 2020, down from 136 in Q3 2020.
- Funds reported $522M of Amphastar Pharmaceuticals stock for Q4 2020, up 6.9% quarter-over-quarter.
- 9 funds opened new Amphastar Pharmaceuticals positions in Q4 2020 and 16 closed out, a net change of -7 holders.
- The largest Amphastar Pharmaceuticals buyer in Q4 2020 was Federated Hermes, an estimated $9.45M added.
- The largest Amphastar Pharmaceuticals seller in Q4 2020 was Fuller & Thaler Asset Management, an estimated $5.28M sold.
Based on aggregated 13F filings for Q4 2020.